|Mr. Christian S. Schade||Pres, CEO & Director||593.28k||N/A||1961|
|Dr. Gregory A. Korbel Ph.D.||VP of Bus. Devel.||276.45k||N/A||1976|
|Mr. Scott M. Coiante||Sr. VP & CFO||N/A||N/A||1967|
|Dr. Lars B. Abrahmsén||Sr. VP & Chief Scientific Officer||N/A||N/A||1957|
|Dr. Eyal C. Attar M.D.||Sr. VP & Chief Medical Officer||N/A||N/A||1970|
Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Aprea Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.